ReviewiScience2026
Noncoding RNA encoded peptides in tumors from discovery to mechanism and clinical translation.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcripts annotated as noncoding can produce peptides, but detecting translation does not establish peptide function. The central problem is to determine which instances of ribosome engagement lead to productive translation, which cancer phenotypes depend on the peptide rather than the source RNA, and which validated products are clinically relevant. This Review addresses that problem through a graded evidence framework that proceeds from transcript architecture and ribosome engagement to endogenous peptide detection and causal attribution to the peptide. Under this standard, validated peptides act at molecular control points where local concentration or enzymatic amplification can reconcile low abundance with biological effect. On that basis, we define the conditions required for actionability: tumor-enriched expression, reproducible endogenous measurement, a defined mechanism, and an intervention matched to that mechanism. Progress therefore depends on causal attribution, not on longer candidate lists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.